Tryptamine Compositions for Enhancing Neurite Outgrowth
Summary
US Patent Application US20260108544A1, filed February 7, 2025 and published April 23, 2026, covers neurotrophic and nootropic compositions comprising tryptamines from psilocybin-containing mushrooms, optionally combined with phenethylamines, amphetamines, erinacines, hericenones, and cannabinoids. The application names Paul Edward Stamets as inventor and lists multiple CPC classifications spanning pharmaceutical chemistry and botanical extracts. This publication makes the application publicly available for review and potential opposition prior to grant.
“Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108544A1 for neurotrophic and nootropic compositions containing tryptamines derived from psilocybin-containing mushrooms, optionally combined with phenethylamines, amphetamines, erinacines, hericenones, and/or cannabinoids. The application names Paul Edward Stamets as sole inventor and specifies multiple CPC chemical classifications spanning A61K pharmaceutical preparations.
Affected parties include pharmaceutical and biotechnology firms researching neuroplasticity, psychedelic-assisted therapy, and nootropic supplement development. The published application provides public notice of the claimed composition scope, allowing competitors to assess freedom-to-operate and potential licensing needs before the patent grants.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
Application US20260108544A1 Kind: A1 Apr 23, 2026
Inventors
Paul Edward STAMETS
Abstract
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
CPC Classifications
A61K 31/661 A61K 9/08 A61K 31/05 A61K 31/352 A61K 31/4045 A61K 31/455 A61K 31/658 A61K 36/06 A61K 36/066 A61K 36/07 A61K 36/3482 A61K 36/73 A61P 25/24
Filing Date
2025-02-07
Application No.
19048753
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.